Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Axel Glasmacher, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Janssens Uwe, MD, Jorg Schubert, MD, Patrick Bruck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, PhD, Susanne Herz, Marie von Lilienfeld-Toal, MD, Ralf Naumann, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2007) 110 (11): 4825.

https://doi.org/10.1182/blood.V110.11.4825.4825

Published: 2007

Journal Articles

Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment.

Ingo G.H. Schmidt-Wolf, MD, Hendrick Pels, MD, Annika Jurgens, MD, Axel Glasmacher, MD, Holger Schulz, MD, Andreas Engert, MD, Michael Linnebank, MD, Gabriele Schackert, MD, Heinz Reichmann, MD, Frank Kroschinsky, MD, Marlies Vogt-Schaden, MD, Gertlinde Egerer, MD, Carlo Schaller, MD, Monika Lamprecht, MD, Ulrich Bogdahn, MD, Martina Deckert, MD, Rolf Fimmers, MD, Christoph Bangard, MD, Uwe Schlegel, MD

Blood (2007) 110 (11): 4440.

https://doi.org/10.1182/blood.V110.11.4440.4440

Published: 2007

Journal Articles

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Ingo G.H. Schmidt-Wolf, MD, Thomas Moehler, MD, Hartmut Goldschmidt, MD, Thomas Geer, MD, Rolf Kleinschmidt, MD, Tobias Gaska, MD, Uwe Janssens, MD, Joerg Schubert, MD, Patrick Brueck, MD, Michael R. Clemens, MD, Wolfgang Bair, MD, Gernot Seipelt, MD, Michael Schleuning, MD, Corinna Hahn-Ast, Ph.D., Susanne Herz, Ph.D., Marie von Lilienfeld-Toal, M.D., Ralph Naumann, MD, Marcus Gorschlueter, MD, Axel Glasmacher, MD

Blood (2006) 108 (11): 3559.

https://doi.org/10.1182/blood.V108.11.3559.3559

Published: 2006

Journal Articles

Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

Ingo G.H. Schmidt-Wolf, MD, Hendrik Pels, MD, Annika Juergens, MD, Axel Glasmacher, MD, Holger Schulz, MD, Frank Kroschinsky, MD, Gertlinde Egerer, MD, Monika Lamprecht, MD, Caecilia Wismeth, MD, Uwe Schlegel, MD

Blood (2006) 108 (11): 2452.

https://doi.org/10.1182/blood.V108.11.2452.2452

Published: 2006

Journal Articles

Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

Ingo G.H. Schmidt-Wolf, MD, Annika Juergens, MD, Hendrik Pels, MD, Axel Glasmacher, MD, Holger Schulz, MD, Andreas Engert, MD, Michael Linnebank, MD, Heinz Reichmann, MD, Frank Kroschinsky, MD, Marlies Vogt-Schaden, MD, Gerlinde Egerer, MD, Klaus Fliessbach, MD, Uwe Schlegel, MD

Blood (2006) 108 (11): 2453.

https://doi.org/10.1182/blood.V108.11.2453.2453

Published: 2006

Journal Articles

Thalidomide in Relapsed or Refractory Patients with Multiple Myeloma: Monotherapy or Combination Therapy? A Report from Systematic Reviews.

Axel Glasmacher, MD, Corinna Hahn, PhD, Florian Hoffmann, Kerstin Furkert, Marie von Lilienfeld-Toal, MD, Katjana Orlopp, MD, Ralph Naumann, MD, Hartmut Goldschmidt, MD, Ingo G.H. Schmidt-Wolf, MD, Marcus Gorschlueter, MD

Blood (2005) 106 (11): 5125.

https://doi.org/10.1182/blood.V106.11.5125.5125

Published: 2005

Journal Articles

High Dose Chemotherapy with Autologous Stem Cell Transplantation in Malignant Lymphoma - A Single Center Experience.

Ulrich J.M. Mey, MD, Vandana Jha, Marcus Gorschlueter, MD, John W. Strehl, MD, Tilman Sauerbruch, MD, Axel G. Glasmacher, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2005) 106 (11): 5483.

https://doi.org/10.1182/blood.V106.11.5483.5483

Published: 2005

Journal Articles

Nurselike Cells in Chronic Lymphocytic Leukemia Have Gene Expression Profiles and Functional Characteristics That Are Distinct from Those of Monocytes or Dendritic Cells.

Davorka Messmer, PhD, Tomoyuki Endo, MD, Bradley T. Messmer, PhD, Danelle James, MD, Nathan J. Zvaifler, MD, Ingo G.H. Schmidt-Wolf, MD, Kipps J. Tom, MD, PhD

Blood (2005) 106 (11): 1183.

https://doi.org/10.1182/blood.V106.11.1183.1183

Published: 2005

Journal Articles

Polychemotherapy in patients with primary CNS lymphoma.

Axel Glasmacher, MD, Hendrik Pels, MD, Christoph Helmstaedter, MD, Martina Deckert, MD, Frank Kroschinsky, MD, Gabriele Schackert, MD, Heinz Reichmann, MD, Gerlinde Egerer, MD, Anthony Ho, MD, Holger Schulz, MD, Andreas Engert, MD, Volker Diehl, MD, Udo Bode, MD, Thomas Klockgether, MD, Uwe Schlegel, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 3304.

https://doi.org/10.1182/blood.V104.11.3304.3304

Published: 2004

Journal Articles

Cytotoxic Activity of Cytokine-Induced Killer Cells Correlates with Expression of SAP and SLAM.

Stefan Mehrle, Susanne Frank, Ph.D., Jan Schmidt, MD, Markus W. Buchler, MD, Ingo G.H. Schmidt-Wolf, MD, Angela Marten, Ph.D.

Blood (2004) 104 (11): 3874.

https://doi.org/10.1182/blood.V104.11.3874.3874

Published: 2004

Journal Articles

Pulsing with Blast Cell Lysate or Blast-Derived Total RNA Reverses the Dendritic Cell-Mediated Increase in Cytotoxic Activity of Cytokine-Induced Killer Cells Against Human Allogeneic Acute Myelogenous Leukemia Cells.

Bjorn Schottker, MD, Angela Marten, PhD, Carsten Ziske, MD, Marcus Gorschluter, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 4531.

https://doi.org/10.1182/blood.V104.11.4531.4531

Published: 2004

Journal Articles

A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Ulrich J.M. Mey, MD, John W. Strehl, MD, Katjana S. Orlopp, MD, Dimitri Flieger, MD, J. Birkmann, MD, Anthony Ho, MD, U. Kaiser, MD, Andreas Neubauer, MD, Axel G. Glasmacher, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 4618.

https://doi.org/10.1182/blood.V104.11.4618.4618

Published: 2004

Journal Articles

Chromosome Aberrations in 130 Patients with Multiple Myeloma Detected by Interphase FISH and Their Diagnostic and Prognostic Relevance.

Axel Glasmacher, MD, Corinna Hahn, Ph.D., Andrea Juttner, Regine Schubert, Barbara Busert, Gesa Schwanitz, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 4938.

https://doi.org/10.1182/blood.V104.11.4938.4938

Published: 2004

Journal Articles

Phase I/II Trial of Dendritic Cells Pulsed with Telomerase.

Angela Marten, Ph.D., Elisabeth Sievers, Ph.D., Peter Albers, MD, Stefan Muller, MD, Christian Franchy, MD, Alexander von Rucker, MD, Holger Strunk, MD, Hans H. Schild, MD, Tilman Sauerbruch, MD, Ingo G.H. Schmidt-Wolf, MD

Blood (2004) 104 (11): 1353.

https://doi.org/10.1182/blood.V104.11.1353.1353

Published: 2004

NARROW

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Early Relapses in Primary CNS Lymphoma (PCNSL) without Intraventricular Treatment.

Multicenter Phase II Trial of Patients with Refractory or Recurrent Multiple Myeloma with Oral Treatment of Thalidomide Combined with Oral Cyclophosphamide, Idarubicin and Dexamethasone.

Necessity of Intraventricular Chemotherapy with the Modified Bonn Protocol in Primary CNS Lymphoma (PCNSL) Patients.

Phase II Trial of the Bonn Polychemotherapy Protocol with Deferred Radiotherapy in Patients with Primary Central Nervous System Lymphoma.

Thalidomide in Relapsed or Refractory Patients with Multiple Myeloma: Monotherapy or Combination Therapy? A Report from Systematic Reviews.

High Dose Chemotherapy with Autologous Stem Cell Transplantation in Malignant Lymphoma - A Single Center Experience.

Nurselike Cells in Chronic Lymphocytic Leukemia Have Gene Expression Profiles and Functional Characteristics That Are Distinct from Those of Monocytes or Dendritic Cells.

Polychemotherapy in patients with primary CNS lymphoma.

Cytotoxic Activity of Cytokine-Induced Killer Cells Correlates with Expression of SAP and SLAM.

Pulsing with Blast Cell Lysate or Blast-Derived Total RNA Reverses the Dendritic Cell-Mediated Increase in Cytotoxic Activity of Cytokine-Induced Killer Cells Against Human Allogeneic Acute Myelogenous Leukemia Cells.

A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.

Chromosome Aberrations in 130 Patients with Multiple Myeloma Detected by Interphase FISH and Their Diagnostic and Prognostic Relevance.

Phase I/II Trial of Dendritic Cells Pulsed with Telomerase.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only